Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Hospira, Inc.    

HOSPIRA, INC.
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensus 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Hospira : Applauds Delaware Governor’s Signing of Biosimilars Legislation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/30/2014 | 06:42pm CEST

LAKE FOREST, Ill., May 30, 2014 - Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today commended Delaware Gov. Jack Markell for his decision to sign Senate Substitute 1 for Senate Bill 118. This law creates a pathway for the substitution of interchangeable biologic drugs and helps pave the way for patient access to cost savings from biosimilar products.

When biosimilars become available in the United States in the coming years, clinicians will have opportunities to provide their patients with greater accessibility to effective and more affordable biologic drugs. The introduction of biosimilars could help the United States save up to $250 billion over 10 years, according to one report.

"The introduction of biosimilars promises to help put new cost-savings in the hands of patients and states, such as Delaware, that are taking early action to establish clear and transparent policies for the substitution of these high-quality and more affordable biologic products," said Paul Audhya, M.D., vice president, Medical Affairs, Hospira.

The governor's signature on Senate Substitute 1 for Senate Bill 118 allows pharmacists to substitute biosimilars for prescribed biological reference products unless the prescribing physician expressly requests the reference biologic.

Hospira is a market leader in biosimilars in Europe, and expects to submit its first biosimilar to the U.S. Food and Drug Administration (FDA) later this year or in early 2015.


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HOSPIRA, INC.
2015HOSPIRA : Announces First Installation of Plum 360™ Infusion System With H..
PU
2015HOSPIRA : Announces First Installation of Plum 360(TM) Infusion System With Hosp..
PR
2015PFIZER : Buy of Hospira Gets Green Light
DJ
2015PFIZER : Gets U.S. Approval to Acquire Hospira, With Divestitures
DJ
2015HOSPIRA : Expert committee BACKS Hospira’s InflectraTM
PU
2015HOSPIRA : Charleston Area Medical Center Integrates Smart Pump Technology to Adv..
PR
2015HOSPIRA : TGA Approves First mAb Biosimilar
PR
2015HOSPIRA : Applauds UK's NICE for Issuing Adoption Resource to Help Drive the Int..
PU
2015PFIZER : Gets EU Green Light for Hospira Merger
DJ
2015HOSPIRA : Pfizer wins EU approval for $15 billion Hospira buy
RE
More news
News from SeekingAlpha
2017Upcoming Events - Panel For Epogen Biosimilar And Ocaliva's Lipid Test For Na.. 
2016ABBOTT : Current Uncertainties Offer A Buying Opportunity 
2016New Management At ICU Medical Has Produced Positive Results 
2016PFIZER : 30%+ Discount With 4% Yield 
2015PREMARKET BIOTECH DIGEST : Trouble For Anticoagulants, Gilead U.S. Hep C Sales 
Chart HOSPIRA, INC.
Duration : Period :
Hospira, Inc. Technical Analysis Chart | US4410601003 | 4-Traders
Income Statement Evolution
Managers
NameTitle
Zena G. Kaufman Senior Vice President-Quality
Paul Greenland Vice President-Biologics
Sector and Competitors